The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ALK has been associated with other types of cancers, including non-small-cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK-rearrangement (ALK-R), and the ALK-tyrosine kinase inhibitor, crizotinib, used in NSCLC patients.
Types of oncogenesis in ALK
There are three types of ALK gene mutations: rearrangement (ALK-R), amplification (ALK-A), and point mutation.
Most mutations of the ALK gene are in the form of a translocation with another partner gene leading to a fusion oncogene. This fusion gene then becomes overly expressed in cancers. In 1994, ALK was originally identified in anaplastic large-cell lymphoma as a fusion partner of nucleophosmin (NPM-ALK) resulting from a chromosomal translocation. 5 Subsequently, ALK-rearrangement (ALK-R) was identified in many different cancers, including inflammatory myofibroblastic tumors, diffuse large B-cell lymphoma, non-small-cell lung cancer (NSCLC), and esophageal squamous cell, colorectal, and breast carcinomas. 6, 7 ALK rearrangements create an oncogenic ALK tyrosine kinase that activates many downstream signaling pathways resulting in increased cell proliferation and survival. 8 Additional gene partners have been discovered in fusion oncogenes with the ALK gene, including TPM3, TFG, CLTCL1, and ATIC (Table 1) . 9 Another type of ALK gene mutation is ALK-A. The oncogenic mechanism of ALK-A was first described in NB cell lines in 2002. The study showed that ALK-A leads to constitutive activation, resulting in the selective activation of SHcC, a docking protein close to the substrate of the ALK receptor. 10 Several studies have reported extra copies of the ALK gene in inflammatory breast cancer, NSCLC, anaplastic large-cell lymphoma, and pulmonary sarcomatoid carcinoma. 
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The last type of ALK gene mutation is point mutation. Secondary resistance is an acquired mechanism after the tumor has been exposed to an ALK inhibitor 2 and most types of resistance are caused by mutations in the target ALK gene, resulting in an inability to inhibit the encoded tyrosine kinase. 11 The first drug resistance point mutations identified were C1156Y and L1196M. 12 Subsequently, several other point mutations conferring drug resistance have been identified, including: G1269A, F1174L, 1151Tins, L1152R, S1206Y, I1171T, G1202, D1203N, and V1180L. [11] [12] [13] [14] ALK rearrangement in non-small cell lung cancer (NSCLC)
Non-small-cell lung cancer accounts for approximately 80-85% of lung cancers and is a leading cause of cancerrelated mortality in both men and women worldwide. [15] [16] [17] [18] ALK gene rearrangement is a driving mutation underlying the development of NSCLC, and has been identified in 5-6% of NSCLC cases. 19 Notwithstanding the substantial evidence linking activated ALK to tumor genesis in these rare tumors, it is fair to say that the considerable current enthusiasm for ALK as a target for cancer therapy is largely driven by the relatively recent finding of a recurring ALK gene translocation in a significant subset of NSCLC. 20, 21 ALK rearrangement appears to be more common in younger patients and never or light smokers diagnosed with adenocarcinoma. Data from several patient series has shown that the median age of ALK positive NSCLC patients is 55 years and approximately 70% of these patients are never smokers. The incidence of ALK positive NSCLC among men and women is similar across the world. 22, 23 ALK mutations were first described in NSCLC in 2007 when a subset (7%) of Japanese patients were found to have EML4 rearrangement with ALK leading to the fusion oncogene EML4-ALK. 24 This rearrangement was an inversion rearrangement from inv.(2) (p21;p23) that results in EML4 replacing the extracellular and intramembranous parts of ALK and fusing with the juxtamembrane domain. The EML4-ALK fusion gene represents a new molecular target. It has been reported that the incidence of ALK rearrangement ranges from approximately 3% to 13% in unselected or selected patients with NSCLC. 23, [25] [26] [27] Because of the different breakpoints on EML4, several variants of the EML4-ALK mutation have been described (Table 2) .
27-29 EML4-ALK variants with differing frequencies are V1 (54.5%), V2 (10%), V3a/V3b (34%), and V5a (1.5%). 28, 29 EML4-ALK translocation can result in constitutive ALK kinase activity and represents an oncogenic addiction pathway in lung cancer. The EML4-ALK gene induced tumor formation in nude mice. 24, 30 EML4-ALK possesses potent oncogenic activity both in vitro and in vivo, and the tumor can quickly be reduced after the administration of ALKtyrosine kinase inhibitors (TKIs). 24, 31 EML4-ALK fusion protein serves as a therapeutic target for an ALK-TKI, and has shown promising results when used to treat NSCLC patients carrying ALK rearrangement. [32] [33] [34] [35] Over the last few years, ALK inhibitors have shown significant benefits in the management of ALKpositive NSCLC compared to conventional chemotherapy. 21, 34, 36 Rearrangements of the ALK gene with partner genes other than EML4 have been described, namely, KIF5B, KLC1, TFG, TPR, HIP1, STRN, DCTN1, SQSTM1, NPM1, BCL11A, and BIRC6 (Table 3) . [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Targeted therapeutic agents, including the TKI crizotinib, have shown clinical efficacy in treating NSCLC patients harboring EML4-ALK gene fusion. 34 Furthermore, a previous study demonstrated that crizotinib is also effective at treating tumors harboring ALK fused with other partner genes, including NPM1 and BCL11A. 34 In addition, other not-yetcharacterized fusions may also exist in solid tumors, including lung cancer. (Table 4) . 19, 52 FISH relies on a spatial separation of the 5 0 -and 3 0 -portions of the ALK gene upon rearrangement, and produces characteristic spilt ALK-specific signals in case of the translocation. The FISH break-apart assay is currently the most reliable approach to ALK testing, but has a number of critical disadvantages. In particular, FISH requires significant time input of extensively trained personnel and cannot be subjected to reasonable automation; furthermore, it demonstrates relatively high failure rates in some sample series and may provide poorly interpretable results in a noticeable fraction of NSCLC cases. [53] [54] [55] Despite these challenges, FISH is still regarded as the gold standard assay for the detection of ALK rearrangements and a comparator for the other ALK detection methods.
The development of highly sensitive ALK diagnostic antibodies has offered an opportunity to detect ALK-driven tumors by a standard IHC method. One of the main advantages of IHC in comparison to FISH and RT-PCR is the detection of the ALK protein, which is the target of ALK inhibitors. Other advantages of IHC are its low cost, short turnaround time, and ease of operation for users. The principle of IHC is based on the fact that activating ALK rearrangements are accompanied by significant overexpression of the catalytic portion of this tyrosine kinase. IHC is generally capable of producing highly reliable results when performed in reference laboratories; however, it requires the standardization of reagents and protocols across pathology laboratories. [55] [56] [57] [58] The Ventana ALK assay used D5F3 antibody is a resultful method of detecting ALK rearrangement. The Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Tucson, AZ, USA) was approved by the US FDA in 2015 as a companion detection test for the use of crizotinib. 59 Several studies have found that there is high concordance between Ventana IHC and FISH. 60, 61 A research analysis of 46 ALK-positive patients reported sensitivity and specificity of the Ventana IHC of 100% and 98.2%, respectively, and the concordance rate between FISH and Ventana IHC was 98.4%. 62 Although the sensitivity of IHC is high for detecting ALK fusion, FISH-positive/IHC-negative cases responding to ALK inhibitors have been reported in the literature. 63 Reverse transcriptase-PCR based assays have not been as widely used as FISH and IHC for ALK testing in NSCLC. However, conventional RT-PCR has significant advantages compared to FISH and IHC. First of all, while FISH and IHC detect relatively indirect signs of the presence of ALK translocation, RT-PCR usually reveals the exact variant of the rearrangement and therefore provides definitive evidence of ALK fusion. Furthermore, RT-PCR has high sensitivity and specificity, with a rapid turnaround time and ease of analysis, and can detect a small number (1%) of ALK-driven NSCLC cells in the presence of normal tissues. [64] [65] [66] In addition, RT-PCR analysis utilizes the same technical platform as other kinds of molecular NSCLC diagnosis, for example EGFR testing. Finally, a number of commercial RT-PCR kits for detection of ALK rearrangements have been developed recently, including: the ALK RGQ RT-PCR Kit (Qiagen, Valencia, CA, USA); the EML4-ALK Fusion Gene Detection Kit (Amoy Diagnostics, Xiamen, China); and EML4 ALK Gene Fusion, PCR (Quest Diagnostics, Secaucus, NJ, USA). 37, 67 However, there are some disadvantages of this platform. First, this method of analysis of RNA samples yields a poor quality of RNA obtained from formalin fixed paraffin-embedded specimens and can only detect known fusion variants. Second, the high sensitivity may lead to a false-positive result. In a previous study, the sensitivity and specificity of RT-PCR were 95.5% and 87.0%, respectively, and the concordance rate between FISH and RT-PCR was 89.0%. 62 Next generation sequencing is a promising method for detecting ALK gene rearrangements. The great advantage of the NGS platform is the detection of known ALK gene fusions. NGS is also superior to other methods because it allows for simultaneous screening of novel ALK fusion partners as well as other lung cancer related gene mutations, fusions, and amplifications. However, there are still many challenges to overcome before this method can be applied to normal laboratory diagnosis of pathology. For example, expertise is needed to analyze and interpret the results, and the cost and turnaround time are high. 68 As NGS has not yet been approved by the US FDA, it can only be used in conjunction with other methods.
All four methodologies show good sensitivity, specificity, and concordance when artifacts were characterized and excluded. However, the choice of diagnostic methodology for ALK rearrangement detection in clinical practice remains a matter of debate. In ambiguous cases at least two of the four methods should be used to confirm ALK rearrangement.
ALK inhibitors
Crizotinib ALK rearrangements in NSCLC have introduced new treatment options for advanced NSCLC with the use of ALKTKIs. 24 ALK fusion proteins can activate many different interconnected and overlapping pathways, such as Ras/Raf/MEK/ ERK1/2, JAK/STAT, PI3K/Akt, and PLC-γ pathways, all of which are involved in cell migration, proliferation, and survival. 8 In addition, several ALK fusion partners have been identified. However, regardless of the involved partners, all chimeras retain the ALK gene kinase domain responsible for the constitutive activation of ALK signaling pathways. 8 Crizotinib is the first ALK inhibitor to enter clinical trials. Crizotinib is a multi-targeted TKI 69 with activity against MET, ALK, and ROS1, and was approved by the US FDA in 2011 for metastatic NSCLC positive for ALK rearrangements. 34, 70, 71 Crizotinib has a reported response rate of over 60% and a disease control rate of up to 90%. 34 Furthermore, median progression-free survival (PFS) exceeds nine months, and median overall survival is almost 75% after one year in ALK-rearranged NSCLC. 72 Comparison of crizotinib treatment with a historical control is instructive. 38 Therefore, from identification to inhibitor approval, the story of ALK in NSCLC stands as a testament of the promises of targeted molecular medicine. 22 
Next generation ALK inhibitors
Unfortunately, almost all patients treated with crizotinib develop tumor progression. As such, potent inhibitors of ALK that can overcome resistance to crizotinib are needed. Several agents have been evaluated in patients with crizotinib refractory NSCLC. Ceritinib and alectinib are currently approved in the US, and brigatinib has received breakthrough designation by the US FDA. The response rates with these agents in patients with crizotinib drug resistance are 50-55%, and the median PFS rates are 6.9 for ceritinib, 8.9 for alectinib, and 15.6 months for brigatinib. [73] [74] [75] Ensartinib is another next generation ALK inhibitor. Ensartinib activity was not only observed in crizotinib-resistant patients but also yielded results in patients who had previously been administered more than two alternate ALK inhibitors. 76 The ASCEND-4 trial evaluated the effects of ceritinib or chemotherapy in randomized ALK-positive treatment naïve patients. 77 The median PFS with ceritinib was 16.6 versus 8.1 months in patients treated with chemotherapy. In the ASCEND-5 trial, patients who initially received chemotherapy and crizotinib were randomized for further treatment of ceritinib or chemotherapy. Results demonstrated a significant improvement in PFS, with a median of 5.4 months after the administration of ceritinib compared to 1.6 months with chemotherapy. 78 These data reveal that ceritinib is the preferred treatment for ALK-positive NSCLC patients.
